International Gene · Excellent Choice
Stable Blood Sugar, Light Weight, Healthy Heart
Vetion®: A Next-Gen GLP-1RA Metabolic Regulator
Vetion is a GLP-1 receptor agonist metabolic therapeutic drug with Semaglutide as its core original component, precisely targeting type 2 diabetes, obesity, and metabolic syndrome. It draws on cutting-edge peptide therapy, mimicking endogenous human GLP-1 hormone to regulate appetite centers and control food intake, achieving significant results in weight loss and blood sugar control, opening up new avenues for metabolic disease treatment.
Product Series
We offer a variety of product specifications to meet the treatment needs of different patients, ensuring efficacy and safety.
Oral Tablets
Semaglutide Tablets
Used for the treatment of type 2 diabetes, helping to control blood sugar levels and improve patients’ quality of life.
Specifications
Multiple dosages available
Injection
Semaglutide Injection
GLP-1 receptor agonist, used for the treatment of type 2 diabetes and obesity, once weekly injection.
Specifications
0.25mg-2.4mg
Injection
Tirzepatide Injection
Dual receptor agonist, effectively controls blood sugar and weight, suitable for patients with type 2 diabetes.
Specifications
Multiple dosages available
Oral Tablets
Semaglutide Tablets
Used for the treatment of type 2 diabetes, helping to control blood sugar levels and improve patients’ quality of life.
Specifications
Multiple dosages available
Injection
Semaglutide Injection
GLP-1 receptor agonist, used for the treatment of type 2 diabetes and obesity, once weekly injection.
Specifications
0.25mg-2.4mg
Injection
Tirzepatide Injection
Dual receptor agonist, effectively controls blood sugar and weight, suitable for patients with type 2 diabetes.
Specifications
Multiple dosages available
Product Features
GLP-1 Weight Loss Mechanism
GLP-1 is an important glucagon-like peptide that plays a wide range of physiological roles in the human body. Especially in patients with type 2 diabetes, GLP-1 has the ability to regulate blood sugar and improve metabolic function, making it an important drug in diabetes treatment.
GLP-1 hormone slows down gastric emptying, allowing food to stay in the stomach longer. This helps diabetic patients better control blood sugar, and can also control appetite by prolonging satiety, thereby creating a calorie deficit.
Healthy Weight
Management
Control
Long-Acting Mechanism
Specially modified molecular structure significantly extends action time in the body, activating GLP-1 receptors.
Potent Blood Sugar Lowering Effect
Excellent ability to reduce HbA1c, superior to many other oral or injectable antidiabetic drugs.
Cardiovascular Benefits
Large cardiovascular outcome trials have proven significant reduction in major adverse cardiovascular events.
Significant Weight Loss Effect
Effectively reduces appetite, increases satiety, and decreases calorie intake, leading to significant and sustained weight loss.
Good Safety Profile
Most common adverse reactions are gastrointestinal, usually mild to moderate and temporary.
Multiple Specifications Available
Offers various dosage specifications, allowing doctors to flexibly adjust based on treatment goals and individual patient conditions.
Product Comparison
Semaglutide vs. Tirzepatide vs. Other Peptide Products: Providing comprehensive data comparison on weight loss, blood sugar reduction, and cardiovascular benefits.
Product Advantages
High Purity Quality Assurance
Utilizing industry-leading biotechnology for production, with strict control from raw materials to finished products, maximizing the retention of active pharmaceutical ingredients to ensure excellent efficacy and high safety, safeguarding patient treatment.
Cost-Effective Choice
While maintaining uncompromised quality, we innovate pricing models to reduce patient treatment costs, demonstrating corporate social responsibility and making high-quality treatment accessible to more people.
Full-Spectrum Formulation
We offer a globally rare oral + injectable dual-formulation GLP-1 solution, covering the patient’s entire treatment cycle—Semaglutide tablets enhance convenience (no injection needed), while injectable forms ensure continuous blood sugar control and weight management. Tirzepatide is a dual-target (GIP/GLP-1) injectable, offering superior efficacy for severe metabolic diseases.
Multi-Target Precision Therapy
Our product portfolio includes both single-target (Semaglutide) and dual-target (Tirzepatide) GLP-1 therapies: Semaglutide: long-term blood sugar control (HbA1c ↓1.8-2.4%) + 26% cardiovascular risk reduction; Tirzepatide: achieves over 40% weight loss and metabolic improvement through dual GIP/GLP-1 activation.
Customer Trust & Reviews
Real feedback from medical professionals and patients, witnessing the quality and effectiveness of our products
Manager Zhang
"Vetion's Semaglutide injection has performed exceptionally in my clinical practice. Patients have shown significant improvements in blood sugar control and weight management. I am very satisfied with its quality and efficacy."
Coach Li
"After taking Vetion's Semaglutide tablets, my blood sugar has stabilized significantly and I've started losing weight. I feel much more energetic and healthier overall."
General Manager Wang
"Tirzepatide, as a dual-target agonist, shows great potential in metabolic disease treatment. Vetion's products are of high purity and efficacy, making them a trustworthy choice."
GLP-1 Frequently Asked Questions
Learn more about the mechanism of action, suitable populations, side effects, and precautions for GLP-1 drugs
GLP-1 (Glucagon-like peptide-1) receptor agonists are a class of drugs that mimic the GLP-1 hormone naturally secreted by the human intestine. By activating GLP-1 receptors, they promote insulin secretion (only when blood sugar is elevated), inhibit glucagon secretion, delay gastric emptying, and increase satiety, thereby lowering blood sugar and reducing weight.
GLP-1 drugs are primarily used to treat type 2 diabetes, helping patients control blood sugar and reduce glycated hemoglobin. In recent years, high-dose GLP-1 drugs have also been approved for the treatment of obesity or overweight adults with related complications to help them achieve significant weight loss.
The most common side effects are gastrointestinal, such as nausea, vomiting, diarrhea, constipation, and abdominal pain. These side effects are usually mild to moderate and tend to decrease as treatment continues or the body adapts. The risk of severe hypoglycemia is low but increases when used in combination with sulfonylureas or insulin.
Semaglutide is a single GLP-1 receptor agonist that primarily acts through the GLP-1 pathway. Tirzepatide is a dual GIP (Glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist that activates both intestinal hormone receptors simultaneously, typically showing more potent effects in blood sugar lowering and weight loss.
Unopened GLP-1 injectable drugs should generally be stored in a refrigerator at 2°C to 8°C (36°F to 46°F) and should not be frozen. After opening, some products can be stored at room temperature (below 30°C/86°F) for a certain period (usually 4 to 6 weeks), while others still require refrigeration. Always follow the specific storage instructions provided with the product.
GLP-1 drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). They should also not be used in patients with a known hypersensitivity to any component of the drug. Pregnant and breastfeeding women should consult their healthcare provider before use.
Still Have Questions? Consult Our Experts
Our professional medical team can provide personalized medication advice and health guidance, answering any questions you have about Semaglutide oral tablets and other products.
